Pleiotropic functional properties of androgen receptor mutants in prostate cancer
- PMID: 18800375
- DOI: 10.1002/humu.20848
Pleiotropic functional properties of androgen receptor mutants in prostate cancer
Abstract
The androgen receptor (AR) signaling pathway plays an important role during the development of the normal prostate gland, but also during the progression of prostate cancer on androgen ablation therapy. Mutations in the AR gene emerge to keep active the AR signaling pathway and to support prostate cancer cells growth and survival despite the low levels of circulating androgens. Indeed, mutations affecting the ligand binding domain (LBD) of the AR have been shown to generate so-called "promiscuous" receptors that present widened ligand specificity and allow the stimulation of these receptors by a larger spectrum of endogenous hormones. Another class of mutations, arising in the amino-terminal domain (NTD) of the receptor, modulate AR interactions with coregulators involved in cell proliferation regulation. Besides characteristics of these well-known types of mutations, the properties of other classes of AR mutants recently described in prostate cancer are currently under investigation. Most interestingly, in addition to their potential role in the mechanisms which allow prostate cancer cells to escape androgen ablation therapy, data suggest that certain AR mutations are present early in the natural history of the disease and may play a role in many aspects of prostate cancer progression. Surprisingly, singular truncated AR devoid of their carboxy-terminal end (CTE) region seem to exert specific paracrine effects and to induce a clonal cooperation with neighboring prostate cancer cells, which may facilitate both the invasion and metastasis processes. In this article, we review the functional properties of different classes of AR mutants and their potential impact on the natural history of prostate cancer. Hum Mutat 0, 1-14, 2008. (c) 2008 Wiley-Liss, Inc.
(c) 2008 Wiley-Liss, Inc.
Similar articles
-
Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells.Cancer Res. 2007 Oct 15;67(20):10067-77. doi: 10.1158/0008-5472.CAN-07-1267. Cancer Res. 2007. PMID: 17942941
-
Androgen receptor action in hormone-dependent and recurrent prostate cancer.J Cell Biochem. 2006 Oct 1;99(2):362-72. doi: 10.1002/jcb.20811. J Cell Biochem. 2006. PMID: 16619264 Review.
-
Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics.Prostate. 2005 Jun 1;63(4):395-406. doi: 10.1002/pros.20191. Prostate. 2005. PMID: 15617028
-
Collocation of androgen receptor gene mutations in prostate cancer.Clin Cancer Res. 2001 May;7(5):1273-81. Clin Cancer Res. 2001. PMID: 11350894
-
The role of the androgen receptor in the development and progression of prostate cancer.Semin Oncol. 1999 Aug;26(4):407-21. Semin Oncol. 1999. PMID: 10482183 Review.
Cited by
-
Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective.Oncol Res. 2023 Jan 12;30(3):137-155. doi: 10.32604/or.2022.026074. eCollection 2022. Oncol Res. 2023. PMID: 37305018 Free PMC article. Review.
-
Bioinspired Lipid Nanocarriers for RNA Delivery.ACS Bio Med Chem Au. 2023 Jan 16;3(2):114-136. doi: 10.1021/acsbiomedchemau.2c00073. eCollection 2023 Apr 19. ACS Bio Med Chem Au. 2023. PMID: 37101812 Free PMC article. Review.
-
Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells.Int J Mol Sci. 2021 Jun 22;22(13):6676. doi: 10.3390/ijms22136676. Int J Mol Sci. 2021. PMID: 34206543 Free PMC article.
-
Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review.Biomolecules. 2021 Mar 25;11(4):492. doi: 10.3390/biom11040492. Biomolecules. 2021. PMID: 33805919 Free PMC article. Review.
-
Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells.Invest New Drugs. 2020 Oct;38(5):1292-1302. doi: 10.1007/s10637-020-00901-w. Epub 2020 Feb 1. Invest New Drugs. 2020. PMID: 32008178
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials